Michigan Medicine 26th Annual Liver Disease Wrap-Up 2023

30 $

+ Include: 9 videos + 7 pdfs, size: 6.45 GB

+ Target Audience: gastroenterologist, internist, family medicine physician, primary care physician

Categories: , , , , , ,

Description

+ Include: 9 videos + 7 pdfs, size: 6.45 GB

+ Target Audience: gastroenterologist, internist, family medicine physician, primary care physician

+ Sample video: contact me for sample video

+ Information:

Experts in Hepatology from the University of Michigan Medical School will present a half-day program for physicians and other health care providers that outlines the most current treatment information for patients with liver diseases and complications. Combining case-based information, research studies, and common practice, presentations and question and answer panels will focus on challenges seen in liver care. This important update in the field of hepatology will give attendees what they need to improve patient treatment and offer better outcomes. After completing this activity, participants will use evidence-based care and therapeutic options to treat common liver conditions seen in the primary care office and will provide care following current guidelines, select appropriate tests and imaging studies, and refer patients when needed.

Target Audience

This activity is appropriate for:
House Officers, Medical Students, Nurse Practitioners, Nurses, Other Healthcare Professionals, Physician Assistants, Physicians, Technicians

In the fields of:
Family Medicine, General Medicine, Hepatology, Internal Medicine, Primary Care

Learning Objectives

At the end of this activity, participant should be able to:

  1. understand the latest developments in the diagnosis and treatment of autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and drug induced liver injury.
  2. identify the medical and behavioral treatment of patients with non-alcoholic fatty liver disease.
  3. recognize recommendations regarding the screening, diagnosis and treatment of patients with hepatitis B, C, and D.
  4. identify prevention and treatment of complications of portal hypertension in patients with cirrhosis including ascites, hepatic encephalopathy, and GI bleeding.
  5. initiate medical and behavioral interventions for patients with alcohol use disorder as well as current standard of care management for patients with alcohol associated hepatitis and cirrhosis.
  6. understand how to use available diagnostic and prognostic biomarkers and non-invasive testing modalities including liver and splenic elastography in the management of patients with chronic liver disease with an emphasis on NASH.

 

+ Topics:

2023 Liver Disease Wrap-Up WEB Brochure_0.pdf
Alcohol Use Disorder and Alcohol-Associated Liver Disease Treatment.pdf
Alcohol Use Disorder and AlcoholAssociated Liver Disease Treatment.mp4
Autoimmune, Metabolic and Drug Induced Liver Disease.mp4
Autoimmune, Metabolic and Drug Induced Liver Disease.pdf
Complications of Portal Hypertension.mp4
Complications of Portal Hypertension.pdf
How and When To Treat Fatty Liver Disease.mp4
How and When to Treat Fatty Liver Disease.pdf
Non-Invasive Tests for Liver Fibrosis in the Outpatient Setting.pdf
Non-Invasive Tests of Liver Fibrosis in the Outpatient Setting.mp4
Question and Answer Panel 1.mp4
Question and Answer Panel 2.mp4
The Latest Recommendations for Hepatitis B, C, and D Management.mp4
The Latest Recommendations for Hepatitis B, C, and D Management.pdf
Dec 9.mp4

Reviews

There are no reviews yet.

Be the first to review “Michigan Medicine 26th Annual Liver Disease Wrap-Up 2023”

Your email address will not be published. Required fields are marked *

Related products